FMC shares drop almost 7% after rimisoxafen submission and ongoing technical weakness

FMC shares drop almost 7% after rimisoxafen submission and ongoing technical weakness
FMC slides 6.89% today to $8.31

FMC Corporation (FMC) dropped 6.89% after persistent selling followed the company's regulatory submission for rimisoxafen, a new herbicide, in Brazil. The downtrend is reinforced by FMC trading well below its 20-day, 50-day, and 200-day moving averages, reflecting broad technical weakness that supports the downward move.

FMC price prediction
24H -2.83%
$3.78
48H -4.88%
$3.7
7D -7.97%
$3.58
1M -35.48%
$2.51
3M -34.96%
$2.53
6M -22.11%
$3.03
12M -61.18%
$1.51
Current price: $3.89 -0.4000 9.32%
Closed 11/20
Daily range 3.89 Arrow from to Icon 4.43
Weekly range 3.89 Arrow from to Icon 5.29
Loading...

Highlights

  • FMC Corporation submitted regulatory documents to Brazilian authorities for rimisoxafen, a new herbicide for resistant broadleaf weeds.
  • FMC continues to expand its product pipeline, following a recent regulatory submission with the U.S. Environmental Protection Agency.
  • Shares of FMC closed at $8.31, firmly below short-, medium-, and long-term moving averages, with technical indicators projecting a trading range of $7.54 to $8.72 over the next five days and a very high probability of further decline.

Rimisoxafen dossier drives pipeline focus amid persistent market outflows

FMC Corporation submitted its regulatory dossier for rimisoxafen, a novel herbicide targeting resistant broadleaf weeds, to Brazilian authorities. This follows a previous submission with the U.S. Environmental Protection Agency, and highlights the company's pipeline expansion. These product development milestones were reported, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees the selling pressure in FMC as a combination of disappointing technical signals and persistent investor skepticism around the rimisoxafen regulatory narrative. The persistent drop below all key moving averages and weak momentum indicators highlight structural issues, with the stock showing no signs of a sustainable bid. The regulatory submission in Brazil fails to spark confidence, exposing the stock to further downside as technical and sentiment factors remain negative. He underscores that the neutral outlook for oscillators does little to counteract the clearly bearish setup. "With overwhelming technical weakness and little relief from recent news, I believe there is considerable risk for FMC to break below $8.22 and potentially test $7.54 in the short term."
Viktoras Karapetjanc, expert at Traders Union, highlights that FMC’s regulatory advances in Brazil signal strategic pipeline growth and long-term opportunity. He believes the stock’s pullback is temporary, primarily driven by broad market sentiment rather than underlying company weakness. With rimisoxafen expanding the product portfolio, Karapetjanc sees scope for renewed institutional interest as approvals progress. "I remain constructive — once technical resistance at $8.44 is cleared, mid-term growth toward $8.72 and beyond is achievable as FMC strengthens its global positioning."
Jainam Mehta, market strategist, notes that FMC sits at a technical crossroads with high volatility and sharply negative momentum but some signs of short-term indecision. He sees tactical potential for reversal plays if rare bullish divergences appear as the price approaches extreme support. The consolidation zone near $8.22 offers a possible contrarian entry if volume picks up and bearish sentiment fades. "A sustained break above $8.44 could quickly shift momentum, but conviction is needed before attempting recovery trades here."
FMC Corporation asset chart
FMC Corporation price dynamics. Source: TradingView.

Entrenched bearish setup as broad moving average breaches persist

FMC is currently trading below its 20-day, 50-day, and 200-day moving averages ($9.74, $10.6, and $13.12, respectively), signaling entrenched selling and confirming bearish trends across all timeframes. Key support is established at the recent low of $8.22, while resistance is capped at $8.44, with further trend confirmation shown by the bearish 50-day/200-day alignment and the Ichimoku Kijun resistance at $10.89. Momentum readings reinforce this negative setup: the MACD issues a sell signal, momentum is negative, and the ADX at 19.2 reflects a weak and neutral trend. RSI hovers near oversold at 35.94 with a sell outlook, CCI persists in negative territory at -72.1, and BBP at -0.18 confirms intraday seller dominance. The Stochastic RSI and Awesome Oscillator both read neutral, reflecting some short-term indecision even as downside pressure persists. Intraday volatility stands at 8.27%.

Earlier, analysts noted that FMC's exit from the Indian market and ongoing restructuring continued to reinforce a bearish technical outlook. This latest move, with the stock remaining entrenched in a downtrend despite a new regulatory submission in Brazil, underscores the prevailing risk of further declines, making the $8.22 support level a critical threshold for downside monitoring.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.